Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6546062 | 1.00 | MME (0.42) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL43483 | 1.00 | MME (0.42) | MMERAB9AACECPA1ACE2 | |
| Hydrochloric Acid SCHEMBL13726045 | 0.97 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL3508862 | 0.81 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL596422 | 0.81 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL596424 | 0.81 | MME (0.41) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL14944823 | 0.81 | KDM5B (0.36) | MMERAB9AACETP53KDM5B | |
| SCHEMBL20981925 | 0.79 | TGFBR1 (0.50) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL15154265 | 0.79 | MME (0.39) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL28470159 | 0.77 | CA14 (0.46) | SMN1; SMN2ALDH1A1MAPTMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016434-A1 | Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative Disorders | KAELIN JR WILLIAM G | 2010-01-21 | — | — | US | claimed |
| US-20080241870-A1 | Culture of mesenchymal cells obtained from mammalian foetus of human origin, hematopoietic modulator capable of activating intracellular signaling, and culture medium; kits; leukemia | NATIONAL CENTRE FOR CELL SCINECES (IN) | 2008-10-02 | — | — | US | claimed |
| EP-1912637-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-04-23 | — | — | EP | claimed |
| EP-1856245-A2 | A COMPOSITION FOR CREATING AN ARTIFICIAL BONE-MARROW LIKE ENVIRONMENT AND USES THEREOF | National Center for Cell Sciences (IN) | 2007-11-21 | — | — | EP | claimed |
| WO-2007009044-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA FARBER CANCER INSTITUTE, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006092650-A2 | A COMPOSITION FOR CREATING AN ARTIFICIAL BONE -MARROW LIKE ENVIRONMENT AND USE THEREOF | NATIONAL CENTRE FOR CELL SCIENCES (IN) | 2006-09-08 | — | — | WO | claimed |
| US-20180271851-A1 | ASSAYS, METHODS AND MEANS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| US-20180271850-A1 | ASSAYS, METHODS AND MEANS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| US-9844546-B2 | Antibody against human HIF hydroxylase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-12-19 | — | — | US | disclosed |
| US-9844546-B2 | Antibody against human HIF hydroxylase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-12-19 | — | — | US | disclosed |
| US-9844546-B2 | Antibody against human HIF hydroxylase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-12-19 | — | — | US | disclosed |
| US-20170088876-A1 | Assays, Methods and Means | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-03-30 | — | — | US | disclosed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20040248139-A1 | Eit-6, a polypeptide encoded by an estrogen regulated gene | DANA-FARBER CANCER INSTITUTE, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040146964-A1 | hydroxylases which act on hypoxia inducible factor alpha (HIF- alpha ) and which are involved in the regulation of the cellular turnover of HIF | ISIS INNOVATION LIMITED (GB) | 2004-07-29 | — | — | US | disclosed |
| WO-2004058252-A2 | ANTI-CANCER AGENTS COMPRISING ALKB INHIBITORS AND ALKYLATING AGENTS | ISIS INNOVATION LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| EP-1379630-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LIMITED (GB) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002074981-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LTD. (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271851-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | MME 1057/4885RAB9A 4535/4885ACE 2656/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | MME 1065/4885RAB9A 3488/4885ACE 4387/4885 |
| US-20170088876-A1 | Assays, Methods and Means | EGLN3, EGLN2, P4HA1 | MME 1057/4885RAB9A 4535/4885ACE 2656/4885 |
| US-20180271850-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | MME 1057/4885RAB9A 4535/4885ACE 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.